CJC-1295 / Ipamorelin Stack vs IGF-1 DES
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profileIGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profile| CJC-1295 / Ipamorelin Stack | IGF-1 DES | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout |
| Administration | Subcutaneous injection (both compounds), Administered together in the same injection | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) |
| Key side effects | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while IGF-1 DES is research-stage.
- Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect).
- Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); IGF-1 DES is 1–2x daily, preferably post-workout.
How each works
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.